Claims for Patent: 9,273,349

Summary for Patent: 9,273,349

Title:	Detection of nucleic acids
Abstract:	This invention provides compositions, methods, and systems for characterizing, resolving, and quantitating single stranded and double stranded DNA and RNA in-situ. Paired sense and anti-sense probes can signal the presence of double stranded nucleic acids. DNA and RNA can be distinguished in cell and tissue samples by hybridizing with probe sets adapted to highlight differences in these targets in-situ.
Inventor(s):	Nguyen; Quan (San Ramon, CA), Ma; Yunqing (San Jose, CA), Lin; Audrey (San Jose, CA), Levinson; Shauna (Los Gatos, CA), Lai; Chunfai (Fremont, CA)
Assignee:	Affymetrix, Inc. (Santa Clara, CA)
Application Number:	13/827,392
Patent Claims:	1. A method for simultaneous detection of DNA and RNA in situ, the method comprising: providing a first set of label extenders capable of hybridizing to a DNA sequence; providing a second set of label extenders capable of hybridizing to an RNA sequence; wherein the first set includes at least three times as many different label extenders as the second set; providing a sample comprising a cell, wherein the cell comprises the DNA sequence and the RNA sequence; simultaneously hybridizing the label extenders of the first set to the DNA sequence and the label extenders of the second set to the RNA sequence in the cell; binding multiple copies of a first label to the first set of label extenders; binding multiple copies of a second label to the second set of label extenders; wherein the first label provides a first detectable signal and the second label provides a second detectable signal that is distinguishable from the first signal; and detecting and distinguishing the first and second signals, thereby detecting and distinguishing the DNA and RNA sequences. 2. The method of claim 1, wherein the first set includes 50 or more different label extenders and the second set includes 16 or fewer different label extenders. 3. The method of claim 1, wherein the DNA sequence encodes the RNA sequence. 4. The method of claim 1, wherein said detecting comprises viewing the sample through a microscope. 5. The method of claim 1, wherein binding multiple copies of a first label to the first set of label extenders comprises hybridizing a first preamplifier to each label extender of the first set and to a plurality of copies of a first amplification multimer and hybridizing a plurality of copies of a first label probe that comprises or is configured to bind to the first label to each copy of the first amplification multimer; and wherein binding multiple copies of a second label to the second set of label extenders comprises hybridizing a second preamplifier to each label extender of the second set and to a plurality of copies of a second amplification multimer and hybridizing a plurality of the copies of a second label probe that comprises or is configured to bind to the second label to each copy of the second amplification multimer. 6. The method of claim 1, wherein the number of nucleotides of the DNA sequence to which the label extenders of the first set collectively hybridize is at least three times greater than the number of nucleotides of the RNA sequence to which the label extenders of the second set collectively hybridize. 7. The method of claim 3, wherein at least part of the DNA sequence to which the label extenders of the first set hybridize is identical to at least part of the RNA sequence to which the label extenders of the second set hybridize. 8. The method of claim 3, wherein the label extenders of the first set hybridize to one or more of intron sequences, anti-sense sequences, and non-coding sequences.

Details for Patent 9,273,349

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2039-02-26